Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 37Other solid neoplasm 37Gastrointestinal 7Gynecologic 6Genitourinary 5Head & Neck 3Dermatologic 3Lymphoid 2Endocrine 2Breast 2Sarcoma 1Plasma cell 1Other hematologic neoplasm 1

Conditions

Melanoma 346Carcinoma, Non-Small-Cell Lung 81Skin Neoplasms 71Carcinoma, Renal Cell 51Lung Neoplasms 49Neoplasm Metastasis 47Breast Neoplasms 45Colorectal Neoplasms 44Neoplasms 42Carcinoma, Basal Cell 42Uveal Melanoma 38Squamous Cell Carcinoma of Head and Neck 37Carcinoma, Merkel Cell 36Ovarian Neoplasms 35Sarcoma 31Lymphoma, T-Cell, Cutaneous 31Pancreatic Neoplasms 26Prostatic Neoplasms 24Carcinoma, Hepatocellular 23Stomach Neoplasms 21Head and Neck Neoplasms 21Uterine Cervical Neoplasms 20Urinary Bladder Neoplasms 20Thyroid Neoplasms 20Esophageal Neoplasms 19Brain Neoplasms 18Carcinoma, Squamous Cell 17Mycosis Fungoides 16Carcinoma, Transitional Cell 16Triple Negative Breast Neoplasms 15

Interventions

atezolizumab 1Nivolumab 1Ipilimumab 1Immunoglobulin G 1Etoposide 1Disulfides 1Cyclophosphamide 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Mesothelioma, Malignant × Dermatologic × 90 days × Clear all
NCT06362369 2026-04-13

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

7 Hills Pharma, LLC

Phase 1/2 Recruiting
126 enrolled
DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Turcot syndrome, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Melanoma, Neoplasm Metastasis, Skin Neoplasms, Colorectal Neoplasms

NCT03420963 2026-03-20

Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors

M.D. Anderson Cancer Center

Phase 1 Terminated
12 enrolled
DermatologicGenitourinaryHead & NeckOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Bone Neoplasms, Endocrine Gland Neoplasms, Melanoma, Mouth Neoplasms, Pharyngeal Neoplasms, Sarcoma, Skin Neoplasms, Thyroid Neoplasms, Urologic Neoplasms

NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
133 enrolled
DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡